ACST - Acasti Pharma Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.71
-0.01 (-2.03%)
As of 10:01AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.72
Open0.71
Bid0.70 x 1000
Ask0.72 x 1200
Day's Range0.71 - 0.72
52 Week Range0.60 - 3.36
Volume25,285
Avg. Volume259,525
Market Cap28.042M
Beta1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.70
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
Trade prices are not sourced from all markets
  • GlobeNewswire14 days ago

    Acasti Pharma Reports on Positive Feedback Following Today’s Presentation at the XVIII International Symposium on Atherosclerosis

    CaPre was featured in an industry breakfast symposium, entitled “Omega-3, Triglycerides, and CVD: Current Status and Future Directions,” presented by Dr. Harold Bays, an investigator in the Company’s phase 3 TRILOGY clinical trials for CaPre, on June 11, 2018 at 7:00 a.m. to 8:30 a.m. Eastern time.  Dr. Bays, MD, FOMA, FTOS, FACC, FACE, FNLA is the Medical Director / President of the Louisville Metabolic and Atherosclerosis Research Center, in Louisville, KY, USA. The breakfast symposium highlighted recent developments in the field of hypertriglyceridemia.  Pierre Lemieux, Ph.D., COO and CSO of Acasti Pharma, followed Dr. Bays’ presentation with a brief corporate presentation on Acasti Pharma, including an update on the progress of the phase 3 TRILOGY clinical trials for CaPre.

  • GlobeNewswire19 days ago

    Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis

    LAVAL, Québec, June 06, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (ACST) (ACST.V) (the “Company” or “Acasti Pharma”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the Company is scheduled to present at this year’s XVIII th International Symposium on Atherosclerosis (ISA2018), the premier conference for international atherosclerosis research. CaPre will be featured in an industry breakfast symposium, entitled “Omega-3, Triglycerides, and CVD: Current Status and Future Directions,” presented by Dr. Harold Bays, an investigator in the Company’s phase 3 TRILOGY clinical trials for CaPre, on June 11, 2018 at 7:00 a.m. to 8:30 a.m. Eastern time.  Dr. Bays, MD, FOMA, FTOS, FACC, FACE, FNLA is the Medical Director / President of the Louisville Metabolic and Atherosclerosis Research Center, in Louisville, KY, USA.

  • GlobeNewswire21 days ago

    Acasti Pharma Appoints Brian Groch as Chief Commercial Officer

    LAVAL, Québec, June 04, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (ACST) (ACST.V) (the “Company” or “Acasti Pharma”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced the appointment of Brian Groch as Chief Commercial Officer. Mr. Groch brings over 25 years of senior experience in the healthcare and life science industries, including product commercialization, developing and executing global sales strategies, business development, and operations.

  • GlobeNewswirelast month

    Acasti Pharma Retains Crescendo Communications for Investor Relations Services in the United States

    LAVAL, Québec, May 18, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (ACST) (ACST.V) (the “Company” or “Acasti Pharma”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it has retained Crescendo Communications, LLC ("Crescendo”) to provide investor relations services for the Company in the United States. “We look forward to working closely with Acasti Pharma to help increase awareness of the Company within the investment community,” said David Waldman, CEO of Crescendo Communications.  “Phase 1 and phase 2 clinical results suggest CaPre® has the potential to become the “best-in-class” cardiovascular drug for treating severe Hypertriglyceridemia (HTG), with approximately three to four million people diagnosed in the U.S. alone (Archives of Internal Medicine, “The Ford Study”, 2009).

  • GlobeNewswirelast month

    Acasti Pharma Announces Full Exercise of Over-Allotment Option

    Acasti Pharma Inc. (ACST) (ACST.V) (the “Company” or “Acasti”) is pleased to announce that Mackie Research Capital Corporation (the “Underwriter”) has fully exercised the over-allotment option (the “Over-Allotment Option”) for additional aggregate gross proceeds to the Company of $1,500,975.  This over-allotment option is related to the previously announced closing of its underwritten public offering (the “Offering”) of units of the Company (“Units”) at a price of $1.05 per Unit (the “Offering Price”) for gross aggregate proceeds to the Company of $10,006,500 pursuant to an underwriting agreement (the “Underwriting Agreement”) dated April 24, 2018 with the Underwriter as sole bookrunner and underwriter. Pursuant to the Over-Allotment Option, the Company issued an additional aggregate of 1,429,500 Units at the Offering price.

  • GlobeNewswire2 months ago

    Acasti Pharma Announces Closing of $10 Million Underwritten Offering

    Acasti Pharma Inc. (ACST) (ACST.V) (the “Company” or “Acasti”) is pleased to announce that it has closed its previously announced underwritten public offering (the “Offering”) of units of the Company (“Units”) at a price of $1.05 per Unit (the “Offering Price”) for gross aggregate proceeds to the Company of $10,006,500 pursuant to an underwriting agreement (the “Underwriting Agreement”) dated April 24, 2018 with Mackie Research Capital Corporation (the “Underwriter”), as sole bookrunner and underwriter.

  • GlobeNewswire2 months ago

    Acasti Pharma Appoints Donald Olds to its Board of Directors and Audit Committee

    LAVAL, Québec, April 27, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (ACST) (ACST.V), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it has appointed Donald Olds to its Board of Directors and Audit Committee. “We are very pleased to welcome Don as a new independent director to Acasti’s Board and a member of our Audit Committee.

  • GlobeNewswire2 months ago

    Acasti Pharma Prices $10 Million Underwritten Offering

    NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.. LAVAL, Quebec, April 24, 2018-- Acasti Pharma Inc. is pleased to announce that, in connection with its overnight marketed ...

  • GlobeNewswire2 months ago

    Acasti Pharma Announces Overnight Marketed Public Unit Offering

    Acasti Pharma Inc. (ACST) (ACST.V) (the “Company” or “Acasti”) is pleased to announce that it has filed a preliminary short form prospectus in connection with an overnight marketed public offering (the “Offering”) of units of the Company (“Units”), with each such Unit comprising one common share (“Common Shares”) and one common share purchase warrant (“Warrants”) of the Company exercisable at any time up to 5 years following the closing of the Offering. The Offering will be conducted by Mackie Research Capital Corporation, as sole bookrunner and lead underwriter (the “Lead Underwriter”), pursuant to which the Lead Underwriter may syndicate the Offering to a selling group or sub-underwriters (together with the Lead Underwriter, the “Underwriters”).

  • GlobeNewswire3 months ago

    Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

    LAVAL, Québec, April 02, 2018-- Acasti Pharma Inc. announces that in accordance with the terms of its outstanding convertible debentures in the total aggregate principal amount of $2,000,000 issued on ...

  • Marketwired3 months ago

    Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia

    Acasti Pharma Inc. today announced that the first patient has been randomized in the company's TRILOGY Phase 3 program evaluating lead drug candidate CaPre for the treatment of severe hypertriglyceridemia ...

  • Associated Press4 months ago

    Acasti reports 4Q loss

    The Laval, Quebec-based company said it had a loss of 31 cents per share. For the year, the company said its loss was nearly unchanged at $8 million. Annual losses per share dropped to 74 cents from 74 ...

  • Marketwired4 months ago

    Acasti Pharma Reports Third Quarter FY 2018 Financial Results

    Acasti Pharma Inc. , a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, ...

  • Marketwired5 months ago

    Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares

    Acasti Pharma Inc. , a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, ...

  • Marketwired5 months ago

    Acasti Pharma Announces Change to Board of Directors

    Acasti Pharma Inc. , a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, ...

  • Marketwired6 months ago

    Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures

    Acasti Pharma Inc. announces that in accordance with the terms of its outstanding convertible debentures in the total aggregate principal amount of $2,000,000 issued on February 21, 2017 , the Corporation ...

  • Marketwired6 months ago

    Acasti Expands Global Patent Portfolio with Newly Granted Patents in South Korea and Canada

    Acasti Pharma Inc. , an emerging biopharmaceutical company focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, ...

  • ACCESSWIRE6 months ago

    Dawson James Securities Announces Closing of US $10 Million Firm Commitment Offering of Common Shares and Warrants for Acasti Pharma Inc.

    BOCA RATON, FL / ACCESSWIRE / January 2, 2018 / Dawson James Securities, Inc., in conjunction with Acasti Pharma Inc. (NASDAQ: ACST; TSX-V: ACST), completed an underwritten offering of 9,900,990 common ...

  • Marketwired6 months ago

    Acasti Pharma to Present at Biotech Showcase Conference

    Acasti Pharma Inc. , a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, ...

  • ACCESSWIRE6 months ago

    Wired News – Acasti Closes $10 Million Common Share Offering, Intends to Use the Proceeds for Scaling Development of CaPre

    LONDON, UK / ACCESSWIRE / January 02, 2018 / Active-Investors.com has just released a free research report on Acasti Pharma Inc. (NASDAQ: ACST ). If you want access to this report all you need to do is ...

  • Marketwired6 months ago

    Acasti Pharma Announces Closing of US$10 Million Firm Commitment Offering of Common Shares and Warrants

    Acasti Pharma Inc. , a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, ...

  • Marketwired6 months ago

    Acasti Pharma Announces Pricing of US$10 Million Offering of Common Shares and Warrants

    Acasti Pharma Inc. , a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, ...

  • Marketwired7 months ago

    Acasti Pharma Clarifies Term of Proposed Strategic Partnership with Leading China Pharmaceutical Company

    Acasti Pharma Inc. , a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, ...

  • ACCESSWIRE7 months ago

    A Great Acquisition and 1000% Revenue Growth Should Mean Big Near-Term Returns for SBRT Investors

    Still a quiet sub-current in the public markets, investment money is pouring into connected devices and the internet of things. SoftBank's $32 billion purchase of ARM Holdings exemplifies this investment ...